TARDBP and synucleinopathy: These findings suggest that despite shared amyloidopathy, the observed brain volumetric phenotypes, together with their corresponding cognitive and CSF biomarker profiles, represent unique entities within the AD spectrum much like the synucleinopathies, tauopathies and TDP43-proteinopathies.